2026· Indian Journal of Biochemistry & Biophysics· 0 citations
TL;DR
An integrated in silico approach consisting of network pharmacology, molecular docking, molecular dynamics simulation, gene expression profiling using AlzData and cell permeability analysis was used to evaluate the therapeutic efficacy of Trimebutine and Hydroxychloroquine against Alzheimer's disease, establishing stable interactions against AD key targets.
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative pathology worldwide and is marked by the progressive loss of neurons. The current therapeutic armamentarium, which is composed mostly of cholinesterase inhibitors, only provides symptomatic amelioration and is often plagued with undesirable adverse events when chronically administered. Consequently, identification of safer and more efficacious therapeutic alternatives is imperative. Drug repurposing is an inexpensive and time-saving way to uncover new clinical uses for already existing pharmacological agents in the context of AD management. In the current study, an integrated in silico approach consisting of network pharmacology, molecular docking, molecular dynamics (MD) simulation, gene expression profiling using AlzData and cell permeability analysis was used to evaluate the therapeutic efficacy of Trimebutine and Hydroxychloroquine against Alzheimer's disease. The probable target proteins' protein-protein interaction (PPI) network demonstrated non-random connectedness, indicating strong functional linkages. The KEGG pathway enrichment analysis showed that PI3K and Akt are involved in endothelial growth factor (VEGF)-mediated angiogenesis, longevity regulation, and gefitinib resistance pathways, suggesting possible roles in neuroprotection and vascular health. Molecular docking experiments indicated that Trimebutine had a strong sequence homology with 5UBR and 2Y3A, with binding energies of -7.3 and -7.2 kcal/mol, respectively, whereas Hydroxychloroquine bound to 2Y3A at a greater level (-7.0 kcal/mol). Molecular dynamics (MD) simulation validated the stability of the docked complexes, characterized by low RMSD trajectories and persistent hydrogen bond interactions. Both drugs had passive membrane permeability limits, while hydroxychloroquine was somewhat more membrane affine. Trimebutine and Hydroxychloroquine established stable interactions against AD key targets, especially in the PI3K-Akt system, thereby supporting their candidature as repurposed therapeutics for Alzheimer's disease.
Its favorable binding characteristics, electronic stability, and predicted brain permeability highlight apigenin as a potential candidate for the prevention and treatment of neurodegenerative diseases, warranting further experimental and clinical validation.
The need for rational drug design to develop multitargetdirected drugs that may have disease-modifying effects, to overcome the limitations of existing symptomatic cholinesterase-inhibitor monotherapy is underscored.
Anuradha Mehra, Rahul Sharma, Amit Mittal· CNS and Neurological Disorde...· 0 citations
Current preclinical and emerging evidence indicate that the modulation of interconnected pathological pathways, including mitochondrial dysfunction, insulin resistance, and neuroinflammation, may lead to improved therapeutic outcomes, and the incorporation of early diagnostic biomarkers in conjunction with the use of m...
Lalit Parihar, A. Singh, Sanjar Alam· Current Pharmacogenomics and...· 0 citations
Findings provide mechanistic insights into the potential effects of JAK inhibitors in AD and identify pacritinib as a computationally prioritized candidate that warrants experimental validation in appropriate AD models.
L. T. Nguyen, Mai Thi Nguyen, T. Nguyen· Medicina· 0 citations
This research highlights the feasibility of using thiazole-derived AChE, BuChE, MAO-B, and amyloid-β inhibitors as scaffold pharmacophores for developing novel drugs to treat Alzheimer's disease and provides vital guidance on the development of future drugs.
Geetanjali Chaudhary, Deepika Paliwal, Aman Thakur et al.· Mini-Reviews in Medical Chem...· 0 citations
This review comprehensively summarizes and critically analyzes advances reported from 2020 to 2026 in the design, synthesis, biological evaluation, and therapeutic potential of RIV-based hybrid molecules and scaffold modifications for AD treatment.
Nitin Kumar, V. Kushwaha, Gourav Singh et al.· Bioorganic & Medicinal Chemi...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.